// App-Quantinova.ai

385 : Outcomes of advanced urothelial carcinoma following discontinuation of programmed death (PD)-1 or PD-ligand (L)-1 inhibitors.

Researchers

Presenter

  • Guru Sonpavde

Principal Investigators

  • Gregory Russell Pond

  • Stephanie A. Mullane

  • Ana Arlene Ramirez

  • Nicholas J. Vogelzang

  • Andrea Necchi

  • Thomas Powles

  • Joaquim Bellmunt

Medical Centers

  • The University of Alabama Birmingham Comprehensive Cancer Center, Birmingham, AL

  • Ontario Clinical Oncology Group, Hamilton, ON, Canada

  • Bladder Cancer Center, Dana-Farber Cancer Institute, Brigham and Women's Cancer Center, Boston, MA

  • Comprehensive Cancer Centers of Nevada, Las Vegas, NV

  • Carolina Urologic Research Center, The US Oncology Network, Myrtle Beach, SC

  • Istituto Nazionale Tumori, Milano, Italy

  • Barts Cancer Institute, Barts Health, and The Royal Free London NHS Foundation Trust, London, United Kingdom

  • Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA

Locations

  • United States

  • Canada

  • Italy

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Advanced Urothelial Carcinoma

Biomarkers

  • Programmed cell death protein 1

  • Programmed death-ligand 1

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved